US$ 28.50
glp 1 side effects gastroparesis New data links GLP-1 agonists for weight loss with higher risk for pancreatitis, GI events Glucagon-like Receptor-1 agonists for obesity:
Description
doi: 10.2337/DC12-2462

Appetite suppression is part of the goal of GLP-1 agonists, but sometimes these medications work almost too well

Open and accessible to all

The FDA approved the first semaglutide drug for weight loss more than a decade ago, but the so-called GLP-1 market exploded more recently, after the 2021 greenlighting of the GLP-1 drug Wegovy for weight management